Opinion

Video

Considerations for Platinum-based Therapy

Author(s):

Aparna R. Parikh, MD,Marwan G. Fakih, MD

Key factors, particularly neuropathy, drive the discussion for platinum-based therapy for patients with non-refractory mCRC.

Related Videos
Peter Forsyth, MD
Richard Kim, MD, Moffitt Cancer Center
Tiago Biachi, MD, PhD
5 KOLs are featured in this series.
5 KOLs are featured in this series.
Related Content
OncLive - stock.adobe.com
December 2nd 2024

Revisit Every OncLive On Air Episode From November 2024

Alexey Danilov, MD, PhD, Marianne and Gerhard Pinkus Professor of Early Clinical Therapeutics, medical director, Early Phase Therapeutics Program, Systems Clinical Trials Office, co-director, Toni Stephenson Lymphoma Center, professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope; Nicole Lamanna, MD, associate clinical professor, medicine, Hematologic Malignancies Section, Hematology/Oncology Division, Columbia University Herberg Irving Comprehensive Cancer Center
November 25th 2024

Long-Term Data Solidify the Role of Zanubrutinib in R/R CLL: With Alexey Danilov, MD, PhD; and Nicole Lamanna, MD

Alan P. Venook, MD, of UCSF
November 27th 2024

Targeted Therapies Represent Core 2024 NCCN GI Cancer Guideline Advancements

Joleen Hubbard, MD, medical oncologist, Allina Health Cancer Institute
October 31st 2024

SUNLIGHT QOL Data Show Positive Outcomes With Trifluridine-Tipiracil Plus Bevacizumab in CRC : With Joleen Hubbard, MD

Maurie Markman, MD, president, Medicine & Science, City of Hope Atlanta, Chicago, and Phoenix
November 20th 2024

Cancer Clinical Trials: A Relevant Need to Clearly Define the Value to Individual Patients

Sebastian Kaulitzki – stock.adobe.com
November 15th 2024

CHMP Recommends Approval of Nivolumab/Ipilimumab in MSI-H/dMMR mCRC